Health-care companies slid after signs of stress in UnitedHealth Group's business.
The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.
Among other insurers who rely on Medicare demand, Humana shares sold off.
Shares of Eli Lilly soared after the American drug maker's latest glucagon-like peptide pill candidate showed efficacy in a clinical trial on diabetes patients. Investors have long awaited a pill version of the popular obesity-drug injections, and Lilly's pill compared favorably to Novo Nordisk's blockbuster Ozempic product when it came to patients' weight loss.
Shares of Novo Nordisk plunged.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 17, 2025 17:16 ET (21:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。